Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
December 12, 2017 07:30 ET
|
Actinium Pharmaceuticals
Higher cell death observed with Actinium-225 labeled daratumumab with up to ten-fold higher potency as compared to naked daratumuambARC of Daratumumab-Actinium-225 labeled with high yield, high...
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
December 11, 2017 16:15 ET
|
Actinium Pharmaceuticals
Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for...
Actinium Pharmaceuticals to Present at BIO Investor Forum
October 16, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Actinium to present on Tuesday, October 17th at 3 PM PT NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
September 20, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Actinium is now a member of the ASBMT™ Corporate Council - Two day event focused on facilitating dialogue aimed at advancing the field of bone marrow transplantation and cellular therapy NEW YORK,...
Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting
September 13, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Company’s Actimab-A and Actimab-M programs to be presented at the conference NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc (NYSE American:ATNM) (“Actinium” or “the...
Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference
September 06, 2017 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
August 09, 2017 07:30 ET
|
Actinium Pharmaceuticals
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
August 02, 2017 16:05 ET
|
Actinium Pharmaceuticals
Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
July 27, 2017 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
July 06, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Webinar topics will cover FDA Advisory Panel on Mylotarg, developments with other CD33 targeted therapies and update on Actimab-A - Webinar to be led by Dr. Joseph Jurcic, Director of Hematologic...